Latest & greatest articles for ondansetron

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ondansetron or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ondansetron and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ondansetron

1. Ondansetron Prescription Is Associated With Reduced Return Visits to the Pediatric Emergency Department for Children With Gastroenteritis

Ondansetron Prescription Is Associated With Reduced Return Visits to the Pediatric Emergency Department for Children With Gastroenteritis Journal Club Eastern Virginia Medical School Therapy Article Presenter: Drexel Proctor Date: 8/31/20 Citation: Benary D et al, Ondansetron Prescription Is Associated With Reduced Return Visits to the Pediatric Emergency Department for Children With Gastroenteritis, Annals of Emergency Medicine, Ann Emerg Med. 2020 May 26:S0196-0644(20)30262-6. 2020, I. WHAT (...) IS BEING STUDIED? 1. Study Objective Primary objective: to evaluate whether a prescription for ondansetron on discharge from the pediatric ED or urgent care center in patients with vomiting or gastroenteritis was associated with a difference in return rates in 72 hours. Secondary objectives: to evaluate the association between ondansetron prescription and return rates in patients specifically receiving a diagnosis of gastroenteritis, and to assess whether there was an association between an ondansetron

2020 Emergency Medicine Journal Club

2. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial Full Text available with Trip Pro

Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial , , , , , , , Affiliations Expand Affiliations 1 RedHill Biopharma, Tel Aviv, Israel. 2 Arkansas Gastroenterology, PA, North Little Rock Arkansas, USA. 3 New Phase Research & Development, Knoxville, Tennessee, USA. 4 Middleburg Consultants, Takoma Park, Maryland, USA. PMID: 32639235 DOI: Item in Clipboard Bimodal Release Ondansetron Improves Stool

2020 EvidenceUpdates

3. Oral Ondansetron to Reduce Vomiting in Children Receiving Intranasal Fentanyl and Inhaled Nitrous Oxide for Procedural Sedation and Analgesia: A Randomized Controlled Trial (Abstract)

Oral Ondansetron to Reduce Vomiting in Children Receiving Intranasal Fentanyl and Inhaled Nitrous Oxide for Procedural Sedation and Analgesia: A Randomized Controlled Trial Intranasal fentanyl and inhaled nitrous oxide are increasingly combined to provide procedural sedation and analgesia in the pediatric emergency setting. This regimen is attractive because of its nonparenteral administration, but is associated with a higher incidence of vomiting than nitrous oxide alone. We seek to assess (...) whether prophylactic oral ondansetron use could reduce the incidence of vomiting associated with intranasal fentanyl and nitrous oxide for procedural sedation compared with placebo.This was a double-blind, randomized controlled trial of oral ondansetron versus placebo conducted at a single tertiary care pediatric emergency department. Children aged 3 to 18 years with planned sedation with intranasal fentanyl and nitrous oxide were randomized to receive oral ondansetron or placebo 30 to 60 minutes

2020 EvidenceUpdates

4. Does intramuscular ondansetron have an effect on intramuscular ketamine-associated vomiting in children? A prospective, randomized, double blind, controlled study

Does intramuscular ondansetron have an effect on intramuscular ketamine-associated vomiting in children? A prospective, randomized, double blind, controlled study Does Intramuscular Ondansetron Have an Effect on Intramuscular Ketamine-Associated Vomiting in Children? A Prospective, Randomized, Double Blind, Controlled Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Am J Emerg Med Actions 2019 Sep 12 [Online ahead of print] Does Intramuscular Ondansetron Have an Effect on Intramuscular Ketamine-Associated Vomiting in Children? A Prospective, Randomized, Double Blind, Controlled Study

2020 EvidenceUpdates

5. Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial Full Text available with Trip Pro

Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National (...) collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation JAMA Netw Open Actions , 2 (11), e1914988 2019 Nov 1 Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial , , , , , , , , , , , Affiliations Expand Affiliations 1 Feinstein Institute for Medical Research, Donald and Barbara Zucker School of Medicine at Hofstra

2020 EvidenceUpdates

6. Oral Ondansetron Administration to Dehydrated Children in Pakistan: A Randomized Clinical Trial

Oral Ondansetron Administration to Dehydrated Children in Pakistan: A Randomized Clinical Trial Oral Ondansetron Administration to Dehydrated Children in Pakistan: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S (...) Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Pediatrics Actions , 144 (6) Dec 2019 Oral Ondansetron Administration to Dehydrated Children in Pakistan: A Randomized Clinical Trial , , , , , , , Affiliations Expand Affiliations 1 Sections of Pediatric Emergency Medicine and Gastroenterology, Department of Pediatrics, Alberta Children's Hospital and Alberta Children's Hospital Research Institute

2020 EvidenceUpdates

7. Randomized Placebo-controlled Trial of Droperidol and Ondansetron for Adult Emergency Department Patients With Nausea (Abstract)

Randomized Placebo-controlled Trial of Droperidol and Ondansetron for Adult Emergency Department Patients With Nausea The objective was to separately compare effectiveness of 1.25 mg of intravenous (IV) droperidol and 8 mg of IV ondansetron with 0.9% saline placebo for adult emergency department (ED) patients with nausea. A novel primary outcome measure, expected to aid clinical interpretation of reported results, was employed.A randomized controlled trial was conducted at the three EDs (...) that continuation could not result in a finding of superiority.Of 215 patients, 73 (34%), 71 (33%), and 71 (33%) received droperidol, ondansetron, and placebo. Symptom improvement occurred in 75% (95% confidence interval [CI] = 64% to 85%), 80% (95% CI = 69% to 89%), and 76% (95% CI = 64% to 85%), respectively. Mean VAS changes were -29 mm (95% CI = -36 to -23 mm), -34 mm (95% CI = -41 to -28 mm), and -24 mm (95% CI = -29 to -19 mm), respectively. Desired treatment effects were experienced by 77% (95% CI = 65

2019 EvidenceUpdates

8. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. Full Text available with Trip Pro

Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. Evidence for the fetal safety of ondansetron, a 5-HT3 receptor antagonist that is commonly prescribed for nausea and vomiting during pregnancy, is limited and conflicting.To evaluate the association between ondansetron exposure during pregnancy and risk of congenital malformations.A retrospective cohort study nested in the 2000-2013 nationwide Medicaid Analytic eXtract. The cohort (...) trimester, the period of organogenesis.Primary outcomes were cardiac malformations and oral clefts diagnosed during the first 90 days after delivery. Secondary outcomes included congenital malformations overall and subgroups of cardiac malformations and oral clefts.Among 1 816 414 pregnancies (mean age of mothers, 24.3 [5.8] years), 88 467 (4.9%) were exposed to ondansetron during the first trimester. Overall, 14 577 of 1 727 947 unexposed and 835 of 88 467 exposed infants were diagnosed with a cardiac

2018 JAMA

9. Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial Full Text available with Trip Pro

Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial We determine whether single-dose oral ondansetron administration to children with vomiting as a result of acute gastroenteritis without dehydration reduces administration of intravenous fluid rehydration.In this 2-hospital, double-blind, placebo-controlled, emergency department-based, randomized trial conducted in Karachi Pakistan (...) , we recruited children aged 0.5 to 5.0 years, without dehydration, who had diarrhea and greater than or equal to 1 episode of vomiting within 4 hours of arrival. Patients were randomly assigned (1:1), through an Internet-based randomization service using a stratified variable-block randomization scheme, to single-dose oral ondansetron or placebo. The primary endpoint was intravenous rehydration (administration of ≥20 mL/kg of an isotonic fluid during 4 hours) within 72 hours

2018 EvidenceUpdates

10. Ondansetron

Ondansetron Top results for ondansetron - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ondansetron The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

11. Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial (Abstract)

Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial We compare aromatherapy with inhaled isopropyl alcohol versus oral ondansetron for treating nausea among emergency department (ED) patients not requiring immediate intravenous access.In a randomized, blinded, placebo-controlled trial, we enrolled a convenience sample of adults presenting to an urban tertiary care ED with chief complaints including nausea (...) or vomiting. We randomized subjects to 1 of 3 arms: inhaled isopropyl alcohol and 4 mg oral ondansetron, inhaled isopropyl alcohol and oral placebo, and inhaled saline solution placebo and 4 mg oral ondansetron. The primary outcome was mean nausea reduction measured by a 0- to 100-mm visual analog scale from enrollment to 30 minutes postintervention. Secondary outcomes included receipt of rescue antiemetic medications and adverse events.We enrolled 122 subjects, of whom 120 (98.3%) completed the study

2018 EvidenceUpdates

12. Nausea/vomiting in pregnancy: Ondansetron

Nausea/vomiting in pregnancy: Ondansetron Ondansetron | Prescribing information | Nausea/vomiting in pregnancy | CKS | NICE Search CKS… Menu Ondansetron Nausea/vomiting in pregnancy: Ondansetron Last revised in February 2020 Ondansetron What dosage of ondansetron should I prescribe? For adults 18 years of age and older, prescribe oral ondansetron up to 8 mg twice a day for a maximum of 5 days. Note that the dose is based on that used for chemotherapy, so is for guidance only. [ ; ; ] What (...) are the adverse effects of ondansetron? The most common adverse effects of ondansetron include constipation, headache, and flushing. Other less common adverse effects include hiccups, hypotension, bradycardia, chest pain, arrhythmias, movement disorders, abnormal liver function tests, and seizures. [ ; ] What are the contraindications and cautions when prescribing ondansetron? Ondansetron is contraindicated for people with: Congenital long QT syndrome. Hereditary problems of galactose intolerance, Lapp

2018 NICE Clinical Knowledge Summaries

13. The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery Full Text available with Trip Pro

The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery Multiple animal studies suggest that ondansetron ameliorates opioid-induced hyperalgesia and tolerance. In this study, we aimed to determine if the administration of ondansetron prior to spinal anesthesia would have an effect on intrathecal opioid-induced acute opioid tolerance, postoperative pain, and analgesic requirements in patients undergoing cesarean delivery (...) with spinal anesthesia.Eighty-six patients undergoing elective cesarean delivery were recruited and randomly allocated to receive either 8 mg intravenous ondansetron (n = 44) or placebo (n = 42) in a prospective, double-blind design. All patients received spinal anesthesia consisting of 15 mg bupivacaine, 20 μg of fentanyl, and 100 μg of preservative-free morphine. We used linear mixed-effects models to assess the difference in pain and opioid consumption in the first 24 hours after surgery between the 2

2017 EvidenceUpdates

14. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <em>CYP2D6</em> genotype and use of ondansetron and tropisetron.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team (...) NGC:011251 2017 Aug NEATS Assessment Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez JAG, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017 Aug;102(2):213-8. [30 references] This is the current

2017 National Guideline Clearinghouse (partial archive)

15. Bringing Up the Best Evidence: Ondansetron in nausea/vomiting of pregnancy

Bringing Up the Best Evidence: Ondansetron in nausea/vomiting of pregnancy Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research (...) . www.acfp.ca July 24, 2017 Bringing Up the Best Evidence: Ondansetron in nausea/vomiting of pregnancy Clinical Question: What are the benefits and risks of ondansetron for nausea and vomiting of pregnancy? Bottom Line: Ondansetron may reduce nausea or vomiting of pregnancy by 25% for one in two users, compared to doxylamine/pyridoxine. There is real uncertainty if ondansetron in pregnancy is associated with any risk to the fetus. Some observational studies suggesting congenital or cardiac defects may

2017 Tools for Practice

16. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2D6 Genotype and Use of Ondansetron and Tropisetron GCBell 1 ,KECaudle 2 ,MWhirl-Carrillo 3 ,RJGordon 4 ,KHikino 5 ,CAProws 6 ,AGaedigk 7 , JAGAgundez 8,9 ,SSadhasivam 10,11 ,TEKlein 3 andMSchwab 12,13,14 The 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antago- nists are used in the prevention (...) of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting. CYP2D6 polymorphisms can in?uence the metabolism of some of these drugs (i.e., ondansetron and tropisetron), thereby affecting drug ef?cacy. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for ondansetron and tropisetron based on CYP2D6 genotype (updates at www. pharmgkb.org and cpicpgx.org). The purpose of this guideline is to provide information

2016 Clinical Pharmacogenetics Implementation Consortium

17. Ondansetron and pregnancy: Understanding the data Full Text available with Trip Pro

Ondansetron and pregnancy: Understanding the data Nausea and vomiting of pregnancy (NVP) is a common condition affecting 75% of pregnant women. NVP generally commences early in the first trimester, peaking in severity between 7 and 12 weeks and in over 90% symptoms will have abated by week 20. Thus, the time when women are most likely to have NVP and require treatment coincides with the embryonic period when there is maximum susceptibility to any teratogenic risk. Following the thalidomide (...) tragedy of 55 years ago there is a particular awareness and sensitivity about these potential risks, especially in relation to any medication used to treat NVP. Despite several studies showing no clear benefits of ondansetron over other NVP treatments such as doxylamine, and the paucity of safety data, the off-label prescribing and use of ondansetron to treat NVP has increased significantly worldwide. Albeit based on limited human pregnancy data, ondansetron has not been associated

2015 Obstetric medicine

18. Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines

Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines Published on: October 7, 2015 Project Number: RA0811-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical (...) effectiveness of ondansetron for children with acute gastroenteritis? What is the clinical effectiveness of ondansetron for adults with acute gastroenteritis? What are the evidence-based guidelines for the use of ondansetron for patients with acute gastroenteritis? Key Message Four systematic reviews, three randomized controlled trials, five non-randomized studies, and two evidence-based guidelines were identified regarding ondansetron use for patients with acute gastroenteritis. Tags antiemetics

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

19. Ondansetron for Post-Operative Nausea and Vomiting in Elderly Patients

Ondansetron for Post-Operative Nausea and Vomiting in Elderly Patients TITLE: Ondansetron for Post-Operative Nausea and Vomiting in Elderly Patients: Clinical Effectiveness and Safety DATE: 08 August 2014 RESEARCH QUESTIONS 1. What is the clinical effectiveness of intravenous (IV) ondansetron for the prevention and treatment of post-operative nausea and vomiting in elderly patients? 2. What is the clinical evidence regarding the safety and harms of the use of IV ondansetron for the prevention (...) and treatment of post-operative nausea and vomiting in elderly patients? KEY FINDINGS One randomized controlled trial was identified regarding the clinical effectiveness and harms of intravenous (IV) ondansetron for the prevention and treatment of post-operative nausea and vomiting in elderly patients. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 7), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

20. Antiemetic Use for Nausea and Vomiting in Adult Emergency Department Patients: Randomized Controlled Trial Comparing Ondansetron, Metoclopramide, and Placebo (Abstract)

Antiemetic Use for Nausea and Vomiting in Adult Emergency Department Patients: Randomized Controlled Trial Comparing Ondansetron, Metoclopramide, and Placebo We compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting.A prospective, randomized, double-blind, placebo-controlled trial was conducted in 2 metropolitan EDs in Melbourne, Australia. Eligible patients with ED nausea and vomiting were randomized (...) to receive 4 mg intravenous ondansetron, 20 mg intravenous metoclopramide, or saline solution placebo. Primary outcome was mean change in visual analog scale (VAS) rating of nausea severity from enrollment to 30 minutes after study drug administration. Secondary outcomes included patient satisfaction, need for rescue antiemetic treatment, and adverse events.Of 270 recruited patients, 258 (95.6%) were available for analysis. Of these patients, 87 (33.7%) received ondansetron; 88 (34.1%), metoclopramide

2014 EvidenceUpdates Controlled trial quality: predicted high